What does China’s regulator approval mean for CoronaVac use?

Question

Accepted Answer

China's Regulator Approval Expands CoronaVac Use to the General Public

China's medical products regulator has formally approved Sinovac Biotech's Covid-19 vaccine, CoronaVac, for use by the general public. This signifies a significant expansion of the vaccine's accessibility beyond high-risk groups, making it the second Covid-19 vaccine to receive this broad authorization in China, following Sinopharm's vaccine.
Wider Public Availability

The formal approval by China's National Medical Products Administration allows CoronaVac to be administered to the wider population. Previously, both CoronaVac and the Sinopharm vaccine were primarily used within China's vaccination programme, which prioritised individuals deemed at higher risk of exposure to the virus. This new authorisation permits a much broader application of the vaccine.
Basis for Approval

The decision to approve CoronaVac for general public use was based on two-month results from late-stage clinical trials conducted overseas. While these interim findings were sufficient for regulatory approval, Sinovac has indicated that the final analysis data from these trials has not yet been obtained.
International Authorisations

In addition to its approval in China, CoronaVac has also received emergency use authorisations in several other countries. These include Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay, and Laos, indicating international recognition and acceptance of the vaccine's efficacy and safety profile based on available trial data.

Reading history

Hide →

This history is cleared when the page is closed.

What does China’s regulator approval mean for CoronaVac use?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends